This article is more than 5 years old. Information may no longer be current.

Isis licenses antisense drug to iCo for neovascular eye diseases

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER, Canada — Isis Therapeutics has licensed an antisense drug in development for the treatment of age-related macular degeneration and diabetic retinopathy to iCo Therapeutics, the companies announced in a joint press release.

Isis 13650 is an antisense inhibitor of c-Raf kinase, an enzyme “important in the signal transduction pathway triggered by VEGF and other important growth factors,” according to the release. Preclinical studies have shown that antisense inhibition of c-Raf kinase is associated with a reduction in the formation of new blood vessels in the eye.

Isis 13650 will enter human clinical trials in 2006, according to the press release.

As part of the agreement, iCo will pay Isis an up-front license fee and will be granted worldwide rights to the compound. Financial terms of the deal were not disclosed.